A Phase Ib study of add-on therapy with CK0804 in myelofibrosis with suboptimal ruxolitinib response

Описание к видео A Phase Ib study of add-on therapy with CK0804 in myelofibrosis with suboptimal ruxolitinib response

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promising results of a Phase Ib study investigating add-on therapy with cord blood-derived, CXCR4-enriched T regulatory cells (CK0804) in patients with myelofibrosis (MF) and suboptimal response to ruxolitinib treatment. The safety run-in has shown positive safety results, and the preliminary efficacy in symptom reduction has been encouraging. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео